TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for...
-
Upload
audra-gilbert -
Category
Documents
-
view
213 -
download
0
Transcript of TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for...
![Page 1: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/1.jpg)
TYPE 2 DIABETES MELLITUSTYPE 2 DIABETES MELLITUS
Richard Sachson MD
![Page 2: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/2.jpg)
0
4
8
12
1980 1990 2000 (Estimated)From Centers for Disease Control and Prevention, 2000.
Dia
gnos
ed C
ases
(M
illi
ons)
+17%
+60%
Diabetes: 16 Million and Climbing• Estimated 10.3 million diagnosed + 5.4 million
undiagnosed cases• Type 2 diabetes accounts for 90-95% of cases
![Page 3: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/3.jpg)
Source: Mokdad et al., Diabetes Care 2000;23:1278-83; J Am Med Assoc 2001;286(10).
Diabetes and Gestational Diabetes Trends Among Adults in the U.S., BRFSS 1990, 1995 and 2000
1990 1995
2000
Diabetes in the U.S. Diabetes in the U.S.
< 4% 4-6% > 6% % incidence of diabetes among adults N/A
![Page 4: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/4.jpg)
DIABETES AND GESTATIONAL DIABETES AMONG ADULTS IN THE
U.S. -2001
![Page 5: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/5.jpg)
Type 2 diabetes and CHD: 7-year incidence of fatal/nonfatal MI (East West Study)
MI = myocardial infarction.* These patients had no prior MI at baseline.Haffner SM, et al. N Engl J Med. 1998;339:229–234.
05
101520253035404550
7-y
ea
r in
cid
enc
e ra
te o
f M
I
No prior MI* MI No prior MI* MI
Nondiabetic Diabeticn = 1373 n = 1059
P < 0.001 P < 0.001
4%
19% 20%
45%
![Page 6: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/6.jpg)
Diabetes and Obesity: The Continuing Epidemic
BMI = body mass index.Mokdad AH et al. Diabetes Care. 2000;23:1278-1283; Mokdad AH et al. JAMA. 1999;282:1519-1522; Mokdad AH et al. JAMA. 2001;286:1195-1200.
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
1990 1992 1994 1996 1998 2000
• Prevalence of obesityincreased by 61%since 1991
• More than 50% of US adults are overweight
• Only 43% of obesepersons advised to loseweight during checkups
• BMI and weight gain majorrisk factors for diabetes
Pre
vale
nce
(%
)
kgYear
72
73
74
75
76
77
78
Diabetes
Mean Body Weight
![Page 7: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/7.jpg)
ExcessGlucoseProduction
ReducedGlucoseUptake
Pancreas
MuscleLiver
FFAs = free fatty acids.Adapted from UK Prospective Diabetes Study Group. Diabetes. 1995;44:1249-1258.DeFronzo RA. Diabetes. 1988;37:667-687.
0
25
50
75
100
–10 –6 –2 2 6-C
ell
Fu
nctio
n (
%)
Years After Diagnosis
N = 376
Insulin Resistance:
Defective -Cell Secretion:
Pathophysiology of Type 2 Diabetes
REASN14-6/2000
Pathogenesis of Type 2 Diabetes: InsulinResistance and -Cell Dysfunction
-Cell Dysfunction
Pancreas Liver Muscle Fat
Insulin Resistance
Fat
FFAs
Fasting Hyperglycemia Postprandial Hyperglycemia
![Page 8: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/8.jpg)
Progression of Type 2 Diabetes
Glucose
Relative Function
0
100
200
300
-10 -5 0 5 10 15 20 25 30
50
150
250
350
Years of Diabetes
Insulin Resistance
Insulin Level
Fasting Glucose
Beta cell failure
Post Meal Glucose
At risk for Diabetes
Adapted from D Kendall, R Bergenstal, © International Diabetes Center
![Page 9: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/9.jpg)
Insulin Resistance
FFA production Glucose production
Hyperinsulinemia
Dyslipidemia
T2D
SNS activityAbnormal Na+
handling
HTN
Atherosclerosis
![Page 10: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/10.jpg)
![Page 11: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/11.jpg)
TG = triglycerides; FPG = fasting plasma glucose.Ford ES et al. JAMA. 2002;287:356-359.JAMA. 2001;285:2486-2497.American Association of Clinical Endocrinologists. New ICD-9-CM code for dysmetabolic syndrome X. Available at: http://www.aace.com/members/socio/syndromex.php. Accessed January 10, 2002.
Metabolic Syndrome• Also known as dysmetabolic syndrome, insulin resistance
syndrome, syndrome X, the deadly quartet• Prevalence in the United States: approximately 47 million• Defined by having 3 of the following:
– Abdominal obesity: waist > 40" (men); > 35" (women)– TG 150 mg/dL– HDL < 40 mg/dL (men); < 50 mg/dL (women)– Blood pressure 130/85 mm Hg– FPG 110 mg/dL
• New ICD-9-CM code for dysmetabolic syndrome X is 277.7
![Page 12: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/12.jpg)
Visceral Fat Distribution:Normal vs Type 2 Diabetes
Normal Type 2 Diabetes
2-11
![Page 13: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/13.jpg)
13
Complication Prevalence (%)*Any complication 50Retinopathy 21Abnormal ECG 18Absent foot pulses ( 2) and/or ischemic feet 14 Impaired reflexes and/or decreased vibration sense 7Myocardial infarction/angina/claudication 2-3†
Stroke/transient ischemic attack 1*Some patients had more than 1 complication at diagnosis.†Prevalence of each individual condition.UKPDS = United Kingdom Prospective Diabetes Study.UKPDS Group. Diabetologia. 1991;34:877-890.
Prevalence of Complicationsat Time of Diagnosis: UKPDS
![Page 14: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/14.jpg)
Adult Treatment Panel III (ATP III) Guidelines
National Cholesterol Education Program
![Page 15: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/15.jpg)
Diabetes
In ATP III, diabetes is regarded as a CHD risk equivalent.
![Page 16: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/16.jpg)
Note: The recent NCEP/ATP III guidelines suggest that in patients with triglycerides 200 mg/dL, the “non-HDL cholesterol” be calculated with a goal being < 130.American Diabetes Association. Diabetes Care. 2002;25:S33.
Target Lipid Levels forAdult Patients with Diabetes
< 150 mg/dLTriglycerides:
Men: > 45 mg/dL
Women: > 55 mg/dLHDL Cholesterol:
< 100 mg/dLLDL Cholesterol:
![Page 17: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/17.jpg)
Target BP Patients aged 18 years <130/80 mm Hg
Isolated systolic hypertension180 mm Hg <160 mm Hg160–179 mm Hg of 20 mm Hg
American Diabetes Association. Diabetes Care. 2001;24(suppl 1):S33-S43.
Recommended Treatment Goals for Hypertension for Adults With Diabetes
![Page 18: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/18.jpg)
Aspirin
• Use aspirin therapy ( 75-325 mg/day ) in all adult patients with diabetes and macrovascular disease.
• Consider aspirin therapy for primary prevention in patients over age 40 with diabetes and one or more other CV risk factors ( including obesity ).
• Also consider patients between age 30-40.
![Page 19: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/19.jpg)
Type 2 Diabetes Prevention
![Page 20: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/20.jpg)
IGT = impaired glucose tolerance; BMI = body mass index.Tuomilehto J et al. N Engl J Med. 2001;344:1343-1350.
Finnish Diabetes Prevention Program
• 522 patients with IGT• Age: 40-65 years• Mean BMI: 31 kg/m2
• Intervention: diet and exercise• Mean duration of follow up: 3.2
years
![Page 21: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/21.jpg)
The Finnish Diabetes Prevention Study: Lifestyle Modifications
FPG = fasting plasma glucose; PPG = postprandial glucose.Tuomilehto J et al. N Engl J Med. 2001;344:1343-1350.
0
20
40
60
80
100
Inci
denc
e of
Dia
bete
s(C
ases
/100
0 P
erso
n-Y
ears
)
58%P < .001
-20
-10
0
102-Hour PPGFPG
P < .001
P < .003
Cha
nge
from
Bas
elin
e (m
g/dL
)ControlIntervention (Diet and Exercise)
![Page 22: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/22.jpg)
Quintile Weight Change (%) Risk Reduction (%)
1 11 832 5 613 2 134 No change No change5 3 218
Finnish DPP: Results
Each 3-kg weight loss doubles the benefit.DPP = diabetes prevention program.Tuomilehto J et al. N Engl J Med. 2001;344:1343-1350.
![Page 23: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/23.jpg)
United States Diabetes Prevention Program
• 3234 patients with IGT– 32.3% male; 67.7% female– Mean age: 50.6 years ± 10.7 years
• 55% Caucasian, 20% African American, 16% Hispanic, 9% Asian and American Indian
• Interventions: diet (reduced calorie, 25% fat) and exercise (≥ 150 minutes/week physical activity) or metformin (850 mg b.i.d.)
• Average follow-up: 2.8 years (range: 1.8-4.6 years)
IGT = impaired glucose tolerance. Diabetes Prevention Program Research Group. N Engl J Med. 2002;346:393-403.
![Page 24: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/24.jpg)
Intensive Lifestyle Placebo Intervention Metformin
(n = 1082) (n = 1079) (n = 1073)
Wt loss: 0.1 kg* Wt loss: 5.6 kg* Wt loss: 2.1 kg*
Diabetes: 29%† Diabetes: 14%† Diabetes: 22%†
United States Diabetes Prevention Program: Results
*Average; †Cumulative incidence at 3 years.Diabetes Prevention Program Research Group. N Engl J Med. 2002;346:393-403.
![Page 25: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/25.jpg)
Intensive Lifestyle Placebo Intervention Metformin
(n = 1082) (n = 1079) (n = 1073)
Wt loss: 0.1 kg* Wt loss: 5.6 kg* Wt loss: 2.1 kg*
Diabetes: 29%† Diabetes: 14%† Diabetes: 22%†
Risk reduction: Risk reduction: 58% 31%
United States Diabetes Prevention Program: Results
*Average; †Cumulative incidence at 3 years.Diabetes Prevention Program Research Group. N Engl J Med. 2002;346:393-403.
![Page 26: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/26.jpg)
TREATMENT OF TYPE 2 DIABETES
![Page 27: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/27.jpg)
Therapy for Type 2 Diabetes: Sites of Action
Rosiglitazone
Pioglitazone
Glucose Uptake
Insulin Resistance
=
MuscleHyperglycemia
GutCarbohydrate Metabolism
Miglitol
Acarbose
Hyperglycemia
Metformin
Hepatic GlucoseProduction Hyperglycemia
Liver
Exogenous Insulin Rx
Sulfonylurea
Repaglinide
Nateglinide
Impaired Insulin Secretion
Insulin Deficiency
=
PancreasHyperglycemia
![Page 28: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/28.jpg)
Sulfonylureas
![Page 29: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/29.jpg)
Sulfonylurea Effects on the -cell
SulfonylureaMetabolism
FreeCa++
Glucose
K+
K+ATP Channel
[ATP]
[ADP]
Ca++
VDCC(+)
-Cell
Insulin Release
SUR
Depolarization
Hu S et al. J Pharmacol Exp Ther 2000;293:444–52
![Page 30: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/30.jpg)
Inzucchi SE. JAMA. 2002;287:360-372.
Sulfonylureas• Mechanism of action: increases pancreatic
insulin secretion• Reported A1C reduction: 0.9%-2.5%• Advantages: well-established, decreases
microvascular risk, convenient daily dosing• Disadvantages: hypoglycemia, weight gain,
hyperinsulinemia (role uncertain)• FDA approval status: monotherapy;
combination with insulin, metformin, thiazolidinedione, -glucosidase inhibitors
![Page 31: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/31.jpg)
Second-Generation Sulfonylureas
24 hours5-20Glucotrol XL®
16-24 hours
12-24 hours
16-24 hours
Duration of Action
1-8Amaryl®Glimepiride
5-40*Glucotrol®Glipizide
2.5-20Micronase®, DiaBeta®, Glynase®
Glyburide
Daily Dosage (mg)Trade NamesDrug
*The maximally effective dosage is 20 mg/d, although it is approved for dosages 40 mg/d.DeFronzo RA. Ann Intern Med. 1999;131:281-303.
![Page 32: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/32.jpg)
Nonsulfonylurea Secretagogues
![Page 33: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/33.jpg)
Nonsulfonylurea Secretagogues (Repaglinide or Nateglinide)
• Mechanism of action: increases pancreaticinsulin secretion
• Reported A1C reduction: 0.6%-1.9%• Advantages: targets postprandial glycemia, possibly
less hypoglycemia and weight gain than with sulfonylureas
• Disadvantages: 3-times daily dosing, hypoglycemia, weight gain, no long-term data, hyperinsulinemia (role uncertain)
• FDA approval status: monotherapy; combination with metformin
Inzucchi SE. JAMA. 2002;287:360-372.
![Page 34: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/34.jpg)
Nonsulfonylurea Secretagogues
180-360Starlix®Nateglinide
1.5-16Prandin®Repaglinide
Daily Dosage (mg)Trade NamesDrug
DeFronzo RA. Ann Intern Med. 1999;131:281-303.Starlix® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2000.
![Page 35: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/35.jpg)
Biguanides
![Page 36: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/36.jpg)
Inzucchi SE. JAMA. 2002;287:360-372.
Biguanides (Metformin)• Mechanism of action: decreased hepatic glucose production• Reported A1C reduction: 0.8%-3.0%• Advantages: well established, weight loss, no
hypoglycemia, decreases microvascular risk, decreases macrovascular risk, nonglycemic benefits (decreased lipid levels, increased fibrinolysis, decreased hyperinsulinemia), convenient daily dosing
• Disadvantages: adverse gastrointestinal effects, many contraindications, lactic acidosis (rare)
• FDA approval status: monotherapy; combination with insulin, sulfonylurea, nonsulfonylurea secretagogue, thiazolidinedione
![Page 37: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/37.jpg)
*Serum creatine levels ≥ 1.5 mg/dL in males, ≥ 1.4 mg/dL in females.Glucophage® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2000.
Metformin (Glucophage®) • Usual starting dose is 500 mg b.i.d. or 850 mg q.d. given with meals
– Dosage increases should be made in increments of 500 mg weekly or 850 mg every 2 weeks up to 2000 mg q.d.
– Maximum daily dose of 2550 mg per day• doses > 2000 mg may be better tolerated given t.i.d. with meals
• Contraindications: renal disease or renal dysfunction*, congestive heart failure requiring pharmacologic treatment, known hypersensitivity to the drug, acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma, temporarily discontinue in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials
• Warning: if lactic acidosis is suspected, the drug should be discontinued immediately and general supportive measures promptly instituted
• Precautions: monitoring of renal function, hypoxic states, surgical procedures, alcohol intake, impaired hepatic function, vitamin B12 levels, change in clinical status, hypoglycemia, loss of control of blood glucose
• Pregnancy category B
![Page 38: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/38.jpg)
Thiazolidinediones
![Page 39: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/39.jpg)
Thiazolidinediones• Mechanism of action: increased peripheral glucose disposal• Reported A1C reduction: 1.5%-1.6%• Advantages: reverses one of the primary defects of type 2
diabetes, no hypoglycemia, nonglycemic benefits (decreased lipid levels, increased fibrinolysis, decreased hyperinsulinemia, improved endothelial function), possible beta-cell preservation, convenient daily dosing
• Disadvantages: liver function test monitoring, weight gain, edema, slow onset of action, no long-term data
• FDA approval status: monotherapy; combination with insulin (pioglitazone only), sulfonylurea, metformin
Inzucchi SE. JAMA. 2002;287:360-372.
![Page 40: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/40.jpg)
Thiazolidinediones
15-45Actos®Pioglitazone
2-8Avandia®Rosiglitazone
Daily Dosage (mg)
Trade NamesDrug
DeFronzo RA. Ann Intern Med. 1999;131:281-303.
![Page 41: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/41.jpg)
-Glucosidase Inhibitors
![Page 42: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/42.jpg)
-Glucosidase Inhibitors• Mechanism of action: decreased gut carbohydrate absorption• Reported A1C reduction: 0.4%-1.3%• Advantages: targets postprandial glycemia, no
hypoglycemia, nonsystemic• Disadvantages: t.i.d. dosing, adverse gastrointestinal effects,
no long-term data• Miglitol FDA approval status: monotherapy; combination
with sulfonylurea• Acarbose FDA approval status: monotherapy; combination
with sulfonylurea, insulin, and metformin
Inzucchi SE. JAMA. 2002;287:360-372.
![Page 43: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/43.jpg)
-Glucosidase Inhibitors
25 t.i.d. to 100 t.i.d.
Glyset®Miglitol
25 q.d. to 50-75 t.i.d.
Precose®Acarbose
Daily Dosage
(mg)Trade NamesDrug
DeFronzo RA. Ann Intern Med. 1999;131:281-303.
![Page 44: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/44.jpg)
Combination Therapy
![Page 45: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/45.jpg)
Synergistic Mechanisms of Action of Glyburide and Metformin
ImprovesGlycemicControl
MetforminGlyburide/
Decreases Insulin Resistance• Increases peripheral glucose uptake• Decreases hepatic glucose production• Decreases intestinal absorption of
glucose
Enhances Insulin
Secretion
![Page 46: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/46.jpg)
Complementary Mechanisms of Action
ImprovesImprovesGlycemicGlycemicControlControl
ImprovesImprovesGlycemicGlycemicControlControl
Metaglip™
(glipizide and metformin HCl) tablets
Metformin• Improves insulin sensitivity by
increasing peripheral glucose uptake • Decreases hepatic glucose production• Decreases intestinal absorption of
glucose
Glipizide•Enhances insulin secretionEnhances insulin secretion
Please see full prescribing information, including boxed WARNING regarding Lactic Acidosis.
![Page 47: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/47.jpg)
Avandamet
Avandia + Metformin
![Page 48: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/48.jpg)
Basic Steps in the Management of Type 2 Diabetes
+ +
diet &exercise
Oral monotherapy
insulin
+
Oralcombination
Oral plusInsulin
![Page 49: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/49.jpg)
DeFronzo. Ann Intern Med. 1999;131:281–
303.
InsulinAdvantages• Can control all patients• Used to overcome
glucose toxicity• Flexibility in dosing• Multiple insulin
preparations available• Use during pregnancy
Disadvantages
• Hypoglycemia
• Weight gain
• Parenteral administration
![Page 50: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/50.jpg)
Insulins for Type 2 Diabetes
6868
![Page 51: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/51.jpg)
Pre-Mixed Insulin Analogs
Humalog Mix75/25
75% NPL / 25% Lispro
6969
![Page 52: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/52.jpg)
R
LRL
R
NPH
+
+
Why NPL Was DevelopedWhy NPL Was Developed
L
NPL
L
L
7070
![Page 53: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/53.jpg)
NPL Component Compared to Human NPH
Hours After Injection
00
11
22
33
44
55
66
77
88
00 22 44 66 88 1010 1212 1414 1616
Human NPH (0.4 U/kg)
NPL Component (0.4 U/kg)
n=8 n=8 Non-diabetic Subjects
Glu
cose
Infu
sio
n R
ate
mg
/min
/kg
7171
![Page 54: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/54.jpg)
00 44 88 1212 1616 2020 2424
00
22
44
66
88
1010
1212
Glu
cose
Infu
sio
n R
ate
Glu
cose
Infu
sio
n R
ate
mg
/kg
/min
mg
/kg
/min
HoursHours
LisproLispro
Lispro Mix75/25Lispro Mix75/25
NPLNPL
Lispro Mix75/25: PharmacodynamicsLispro Mix75/25: Pharmacodynamics
Heise T, et al. Diabetes Care. 1998;21:800-803.
![Page 55: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/55.jpg)
NOVOLOG 70/30
![Page 56: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/56.jpg)
Premix Insulin Profiles
Insulin aspart protamine suspension
Insulin aspart30%
70% NeutralProtamine Hagedorn
(NPH)
Human regular30%
70%
NovoLog®
Mix 70/30
Human
Premixed 70/30
![Page 57: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/57.jpg)
Recommended Dosing
Weight (kg*) x units/kg = total daily dose
2/3 or 1/2 AM2/3 or 1/2 AM
1/3 or 1/2 PM1/3 or 1/2 PM
1 kg = 2.2 lbs
Dosing Guidelines
0.2—0.5 for nonobese individuals
0.4 – 0.8 for obese individuals
Obese= BMI over 30Kgm
![Page 58: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/58.jpg)
DIETDIET
![Page 59: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/59.jpg)
Silverware for dietingSilverware for dieting
![Page 60: TYPE 2 DIABETES MELLITUS Richard Sachson MD. 0 4 8 12 198019902000 (Estimated) From Centers for Disease Control and Prevention, 2000. Diagnosed Cases.](https://reader035.fdocuments.in/reader035/viewer/2022070406/56649e0b5503460f94af3dee/html5/thumbnails/60.jpg)
Questions: